Generation of 1E8 Single Chain Fv-Fc Construct Against Human CD59
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Therapeutic approaches using monoclonal antibodies (mAbs) against complement regulatory proteins (CRPs:i.e.,CD46,CD55 and CD59) have been reported for adjuvant cancer therapy. In this study, we generated a recombinant 1E8 single-chain anti-CD59 antibody (scFv-Fc)and tested anti-cancer effect.by using complement dependent cytotoxicity (CDC). Methods: We isolated mRNA from 1E8 hybridoma cells and amplified the variable regions of the heavy chain (VH) and light chain (VL) genes using reversetranscriptase polymerase chain reaction (RT-PCR). Using a linker, the amplified sequences for the heavy and light chains were each connected to the sequence for a single polypeptide chain that was designed to be expressed. The VL and VH fragments were cloned into the pOptiVEC-TOPO vector that contained the human CH2-CH3 fragment. Then, 293T cells were transfected with the 1E8 single-chain Fv-Fc (scFv-Fc) constructs. CD59 expression was evaluated in the prostate cancer cell lines using flow cytometry. The enhancement of CDC effect by mouse 1E8 and 1E8 scFv-Fc were evaluated using a cytotoxicity assay. Results: The scFv-Fc constructs were expressed by the transfected 293T cells and secreted into the culture medium. The immunoreactivity of the secreted scFv-Fc construct was similar to that of the mouse 1E8 for CCRF-CEM cells. The molecular masses of 1E8 scFv-Fc were about 120 kDa and 55 kDa under reducing and non-reducing conditions, respectively. The DNA sequence of 1E8 scFv-Fc was obtained and presented. CD59was highly expressed by the prostate cancer cell line. The recombinant 1E8 scFv-Fc mAb revealed significantly enhanced CDC effect similar with mouse 1E8 for prostate cancer cells. Conclusion: A 1E8 scFv-Fc construct for adjuvant cancer therapy was developed.
Abstract
Background: Therapeutic approaches using monoclonal antibodies (mAbs) against complement regulatory proteins (CRPs:i.e.,CD46,CD55 and CD59) have been reported for adjuvant cancer therapy. In this study, we generated a recombinant 1E8 single-chain anti-CD59 antibody (scFv-Fc)and tested anti-cancer effect.by using complement dependent cytotoxicity (CDC). Methods: We isolated mRNA from 1E8 hybridoma cells and amplified the variable regions of the heavy chain (VH) and light chain (VL) genes using reversetranscriptase polymerase chain reaction (RT-PCR). Using a linker, the amplified sequences for the heavy and light chains were each connected to the sequence for a single polypeptide chain that was designed to be expressed. The VL and VH fragments were cloned into the pOptiVEC-TOPO vector that contained the human CH2-CH3 fragment. Then, 293T cells were transfected with the 1E8 single-chain Fv-Fc (scFv-Fc) constructs. CD59 expression was evaluated in the prostate cancer cell lines using flow cytometry. The enhancement of CDC effect by mouse 1E8 and 1E8 scFv-Fc were evaluated using a cytotoxicity assay. Results: The scFv-Fc constructs were expressed by the transfected 293T cells and secreted into the culture medium. The immunoreactivity of the secreted scFv-Fc construct was similar to that of the mouse 1E8 for CCRF-CEM cells. The molecular masses of 1E8 scFv-Fc were about 120 kDa and 55 kDa under reducing and non-reducing conditions, respectively. The DNA sequence of 1E8 scFv-Fc was obtained and presented. CD59was highly expressed by the prostate cancer cell line. The recombinant 1E8 scFv-Fc mAb revealed significantly enhanced CDC effect similar with mouse 1E8 for prostate cancer cells. Conclusion: A 1E8 scFv-Fc construct for adjuvant cancer therapy was developed.
참고문헌 (25)
- Ramaglia V, "The membrane attack complex of the complement system is essential for rapid Wallerian degeneration", J Neurosci, 27, pp.7663~7672 (2007)
- Wu G, "Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex", Circ Res, 104, pp.550~558 (2009)
- Ziller F, "Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement- regulatory proteins CD55 and CD59", Eur J Immunol, 35, pp.2175~2183 (2005)
- Buettner R, "Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement- dependent cytotoxicity", Mol Cancer Res, 5, pp.823~832 (2007)
- Shi XX, "CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer", Cell Mol Immunol, 6, pp.61~66 (2009)
- Geis N, "Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro", Curr Cancer Drug Targets, 10, pp.922~931 (2010)
- Yan J, "The role of membrane complement regulatory proteins in cancer immunotherapy", Adv Exp Med Biol, 632, pp.159~174 (2008)
- Rushmere NK, "Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer", Int J Cancer, 108, pp.930~936 (2004)
- Jarvis GA, "Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer", Int J Cancer, 71, pp.1049~1055 (1997)
- Sivasankar B, "CD59 blockade enhances antigen-specific CD4＋ T cell responses in humans: a new target for cancer immunotherapy?", J Immunol, 182, pp.5203~5207 (2009)
- Hu W, "A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1", AIDS, 2010, pp.184, 359~368
- Meri S, "Distribution of protectin(CD59), a complement membrane attack inhibitor, innormal human tissues", Lab Invest, 65, pp.532~537 (1991)
- Babiker AA, "Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack", Prostate, 62, pp.105~114 (2005)
- Xu C, "Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy", Prostate, 62, pp.224~232 (2005)
- Watson NF, "Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients", Cancer Immunol Immunother, 55, pp.973~980 (2006)
- Macor P, "In vivo targeting of human neu-tralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab", Cancer Res, 67, pp.10556~10663 (2007)
- Zhao WP, "Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells", Oncol Rep, 21, pp.1405~1411 (2009)
- Imai M, "Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer", Cancer Res, 65, pp.10562~10568 (2005)
- Vaughan TJ, "Human antibodies by design", Nat Biotechnol, 16, pp.535~539 (1998)
- Hoogenboom HR, "Natural and designer binding sites made by phage display technology", Immunol Today, 21, pp.371~378 (2000)
- Choi GH, "Cloning, expression, and characterization of single-chain variable fragment antibody against mycotoxin deoxynivalenol in recombinant Escherichia coli", Protein Expr Purif, 35, pp.84~92 (2004)
- Cao M, "Construction, purification, and characterization of anti- BAFF scFv-Fc fusion antibody expressed in CHO", dhfrcells, 2009, pp.157, 562~574
- Hayden-Ledbetter MS, "CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells", Clin Cancer Res, 15, pp.2739~2746 (2009)
- Choi TH, "Expression of the recombinant single-chain anti-B cell lymphoma antibody", J Biomed Lab Sci, 9, pp.111~121 (2003)
- Hu S, "Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts", Cancer Res, 56, pp.0355~3061 (1996)